Correction of Psoriatic T Cell Signatures by Deucravacitinib

Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · May 4, 2023

Keywords

ClinConnect Summary

**Summary of the Clinical Trial on Deucravacitinib for Psoriasis**

This clinical trial is studying a new treatment, called deucravacitinib, for people with moderate to severe psoriasis, a skin condition that causes red, scaly patches. The main goal is to understand how this treatment affects immune cells in the skin and blood before and after starting the medication. The trial is currently recruiting participants aged between 18 and 80 who have a significant form of psoriasis, meaning their skin condition covers at least 10% of their body and has a specific severity score.

To participate, individuals need to be at least 18 years old and diagnosed with moderate to severe psoriasis. However, some people may not be eligible, such as those who have taken certain medications in the past three months, are pregnant or breastfeeding, or have serious infections or health conditions that could affect their safety during the study. Participants will be closely monitored throughout the trial and can expect regular check-ups to evaluate their skin condition and overall health. This study aims to provide valuable information about how effectively deucravacitinib can improve psoriasis symptoms.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. 18 years of age or older
• • 2. Patients with moderate-severe psoriasis (BSA \>= 10%, PASI \>=12, static Physician's Global Assessment (sPGA) 3 and above)
• Exclusion Criteria:
• • 1. taking systemic immunosuppressives in the last 12 weeks
• • 2. pregnancy
• • 3. severe immunodeficiency (either from genetic or infectious causes).
• • 4. tuberculosis or other active serious infection
• • 5. active systemic malignancy.
• • 6. breast-feeding
• • 7. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.